Conditional relative survival and competing mortality in patients who underwent surgery for lung cancer: A nationwide cohort study.
Jung Eun YooKyungdo HanDong Wook ShinSang Hyun ParkIn Young ChoDong Woog YoonJongho ChoSung-Sik HanPublished in: International journal of cancer (2020)
We aimed to investigate the conditional relative survival (CRS) and competing mortality in patients who underwent surgery for newly diagnosed lung cancer. Using a nationwide population-based database, we calculated 5-year CRS on 1 to 5 years survival after surgery. These rates were reported according to age, sex, socioeconomic status, comorbidities and treatment received. We also estimated cause-specific mortality with the consideration of competing risk. We identified 34 349 patients newly diagnosed with primary lung cancer from 2007 to 2013. The 5-year CRS after surgery was 71.7% at baseline improving steadily to 85.4% by 5 years, suggesting evidence of persistent excess mortality risk. Throughout the period, lung cancer was the most common cause of death, contributing to 83.6% mortality 1 year after surgery and 66.3% 5 years after surgery. Other causes of death included cardiovascular disease and respiratory disease, which increased continuously with time after surgery. CRS rates for patients with lung cancer improved over time but did not reach the level of the general population even 5 years after surgery. Although the main cause of death continues to be lung cancer, death from noncancer causes increased with time after surgery. Evidence-based decisions could be made on the dynamic risk profiles of the patients.
Keyphrases
- newly diagnosed
- end stage renal disease
- cardiovascular disease
- chronic kidney disease
- peritoneal dialysis
- prognostic factors
- cardiovascular events
- emergency department
- risk factors
- minimally invasive
- coronary artery disease
- atrial fibrillation
- metabolic syndrome
- percutaneous coronary intervention
- patient reported
- smoking cessation
- electronic health record
- combination therapy
- adverse drug
- replacement therapy